New International Guideline Published for Diagnosing and Treating Allan-Herndon-Dudley Syndrome
Key Insights
An international team led by Professor Johannes W. Dietrich has published a new clinical guideline for Allan-Herndon-Dudley syndrome (search) in *Hormone Research in Pediatrics*.
The rare X-linked disorder, affecting approximately one in 70,000 male newborns, causes severe developmental disability, muscle weakness, and cardiac arrhythmias with an average life expectancy of just 35 years.
The guideline addresses the complex dosing of TRIAC (search), a non-classical thyroid hormone approved in Europe since early 2025 that can alleviate symptoms and extend life expectancy.
An international working group from Germany and Switzerland has published a comprehensive new clinical guideline for diagnosing and treating Allan-Herndon-Dudley syndrome (search), a rare and devastating congenital disorder of thyroid metabolism. The guideline, led by Professor Johannes W. Dietrich from the Department of Diabetology, Endocrinology, and Metabolism at Ruhr University Bochum St. Josef Hospital (search) and director of the Center for Rare Endocrine Diseases at the Center for Rare Diseases Ruhr (CeSER), appears in the journal Hormone Research in Pediatrics dated April 2, 2026.
Allan-Herndon-Dudley syndrome (search) occurs in approximately one out of every 70,000 male newborns. The disease is caused by a mutation in the MCT8 (search) protein, which severely disrupts the transport of thyroid hormones into and out of certain cell types. Inherited through the X chromosome, the condition leads to severe developmental disorders with consequent major intellectual disability, muscle weakness, and cardiac arrhythmias.
"Patients usually never learn how to speak or walk, and, due to an elevated concentration of the thyroid hormone T3, they usually die prematurely from cardiovascular complications," said Dietrich. "The average life expectancy is 35 years."
A New Therapeutic Option with Complex Dosing
Since early 2025, a new medication has been approved in Europe: TRIAC (search), a non-classical thyroid hormone. This therapy can alleviate some of the symptoms and extend patients' life expectancy. However, the dosage is highly complex, necessitating the development of structured clinical guidance.
The newly published guideline was developed based on extensive research of the literature and the working group's own clinical experience in pediatric neurology and endocrinology. It provides recommendations for a comprehensive, multidisciplinary treatment strategy for patients in all age groups while also considering the monitoring of the most important systems and secondary diseases.
"Because the symptoms and long-term courses associated with this disease can vary widely, individual treatment plans for the patients are necessary," Dietrich emphasized.
The guideline serves as a practical tool for all healthcare professionals who treat and care for patients affected by Allan-Herndon-Dudley syndrome (search), addressing a critical gap in standardized care for this ultra-rare endocrine disorder.